| Name | CPI-455 |
| Description | CPI-455 is a specific KDM5 inhibitor. |
| Cell Research | All cell lines were treated with DMSO, CPI-4203 or CPI-455 for 5 d with two changes of medium and drug. Thereafter, the cells (PC9, Colo205, Hs888, M14, SKBR3 and EVSA-T) were plated at 2×105 cells in six-well plates in triplicate and treated for an additional 9-15 d, depending on the cell line model. The Incucyte HD imaging system was used to monitor numbers of drug-tolerant cells after cells were stained with Nuclear-ID Red stain. (Only for Reference) |
| In vitro | CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4 trimethylation (H3K4me3) and decreases the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents[1]. CPI-455 has a high measured affinity for the target KDM5 proteins. Within 24 hours, CPI-455 and CPI-766 can dose-dependently increases in H3K4me3, but not H3K4me2. IC50 calculation for KDM5 Inhibitor CPI-455 in 3 luminal breast cancer cell lines MCF-7, T-47 and EFM-19 are 35.4, 26.19 and 16.13 μM, respectively. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 5.63 mg/mL (20.21 mM)
|
| Keywords | CPI-455 | Histone Demethylase | CPI455 | CPI 455 | Inhibitor | inhibit |
| Inhibitors Related | LSD1-IN-24 | Tranylcypromine hemisulfate | DDP-38003 dihydrochloride | GSK-LSD1 dihydrochloride | GSK-J4 | FY-21 | Daminozide | Zavondemstat | AS8351 | Procaine hydrochloride | JIB-04 | KDM4-IN-4 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Methylation Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
